Moderna Shares Drop 10% After FDA Refusal on Flu Shot Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy MRNA?
Source: CNBC
- Moderna Stock Drop: Moderna's shares fell 10% after the FDA refused to review its application for the experimental flu shot mRNA-1010, prompting the company to request a meeting with the FDA to clarify the path forward, which could impact its vaccine development and market confidence.
- Humana's Earnings Miss: Despite beating profit and revenue expectations, Humana reported a fourth-quarter loss of $3.96 per share, better than the expected $4.01 loss, leading to a 6.7% drop in stock price, reflecting market concerns about its profitability.
- Generac's Resilience: Generac's stock rose nearly 6% despite missing fourth-quarter earnings expectations, as CEO Aaron Jagdfeld highlighted growth in the data center market, suggesting a potential increase in backlog from key suppliers to hyperscalers in the coming quarters.
- Mattel's Significant Decline: Mattel's adjusted earnings of 39 cents per share fell short of the expected 54 cents, resulting in a 28% drop in stock price, while its guidance for the year also disappointed, indicating serious challenges ahead for the toy manufacturer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 49.830
Low
17.00
Averages
32.47
High
63.00
Current: 49.830
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stocks Recover Losses from Iran
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
See More
US Stock Market Rises on Economic Resilience
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and boosting investor confidence in economic recovery.
- Service Sector Expansion: The US ISM services index unexpectedly rose to 56.1 in February, significantly better than the anticipated 53.5, reflecting the fastest pace of expansion in 3.5 years and further supporting the stock market rally.
- Oil Price Volatility: Crude oil prices surged over 1% due to the closure of the Strait of Hormuz, despite reports suggesting Iran's willingness to discuss terms for ending the conflict, intensifying market concerns over energy supply.
- Market Performance: The S&P 500 index rose by 0.78%, the Dow Jones Industrial Average increased by 0.49%, and the Nasdaq 100 index climbed by 1.51%, reflecting optimistic expectations regarding economic resilience and corporate earnings.
See More
U.S. Markets Increased on Wednesday; Moderna Led the Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. closed higher on Wednesday, indicating a positive market trend.
- Index Gains: The S&P 500 gained 1.29%, the Dow Jones increased by 0.78%, and the Nasdaq rose by 0.49%.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
US Stocks Rise on Economic Strength Amid Iran War Concerns
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and bolstering investor confidence in economic recovery.
- Service Sector Expansion: The US services index unexpectedly rose to 56.1, marking the fastest expansion in 3.5 years, while service price pressures fell to an 11-month low, demonstrating economic resilience that could further drive stock market gains.
- International Situation Impact: Reports of Iran making indirect contact with the US to negotiate an end to the war boosted market sentiment, although Iranian media denied the claims, the hope for an early resolution to the conflict remains.
- Oil Price Volatility: Despite crude oil prices being affected by the Iranian drone attack and the closure of the Strait of Hormuz leading to production cuts in Iraq, the market estimates a risk premium of $18 per barrel, reflecting heightened concerns over energy supply.
See More
Stocks Recover Losses from Iran
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
See More
US Stock Market Rises on Economic Resilience
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and boosting investor confidence in economic recovery.
- Service Sector Expansion: The US ISM services index unexpectedly rose to 56.1 in February, significantly better than the anticipated 53.5, reflecting the fastest pace of expansion in 3.5 years and further supporting the stock market rally.
- Oil Price Volatility: Crude oil prices surged over 1% due to the closure of the Strait of Hormuz, despite reports suggesting Iran's willingness to discuss terms for ending the conflict, intensifying market concerns over energy supply.
- Market Performance: The S&P 500 index rose by 0.78%, the Dow Jones Industrial Average increased by 0.49%, and the Nasdaq 100 index climbed by 1.51%, reflecting optimistic expectations regarding economic resilience and corporate earnings.
See More
U.S. Markets Increased on Wednesday; Moderna Led the Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. closed higher on Wednesday, indicating a positive market trend.
- Index Gains: The S&P 500 gained 1.29%, the Dow Jones increased by 0.78%, and the Nasdaq rose by 0.49%.
See More
Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares
Settlement Announcement: Moderna has entered into a $2.25 billion settlement with Arbutus and Genevant regarding a vaccine patent dispute, with a payment of $950 million due in Q3 2026.
Stock Market Reaction: Following the settlement news, Moderna's shares rose by 16%, reflecting a shift in investor sentiment from bearish to bullish.
Future Liabilities: The settlement resolves all enforcement actions against Moderna but leaves a contingent liability of up to $1.3 billion if further litigation affirms liability.
Analyst Insights: Analysts view the settlement as a positive development that alleviates uncertainty for Moderna's stock, while maintaining a neutral rating with a price target of $41.
See More
Midday Market Moves: Notable Stock Fluctuations
- CoreWeave Partnership: CoreWeave's stock surged 8% following a multiyear agreement with Perplexity, which will utilize CoreWeave's platform for next-generation inference workloads, enhancing its competitive edge in the cloud market.
- Broadcom Earnings Anticipation: Broadcom shares rose 2% as investors await its fiscal first-quarter earnings report, with analysts projecting earnings of $2.03 per share and revenue of $19.18 billion, indicating strong market confidence in its performance.
- Dow Inc Upgrade Impact: Dow Inc's stock increased by 4% after KeyBanc upgraded its rating from sector weight to overweight, citing that rising oil prices will benefit U.S. ethylene producers, reflecting optimistic market expectations for its profitability.
- Moderna Lawsuit Settlement: Moderna's shares climbed 12% after the company agreed to pay up to $2.25 billion to settle a lawsuit with Arbutus Biopharma and Genevant Sciences over a Covid vaccine patent, demonstrating proactive legal risk management.
See More
US Stocks Rise on Economic Strength Amid Iran War Concerns
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and bolstering investor confidence in economic recovery.
- Service Sector Expansion: The US services index unexpectedly rose to 56.1, marking the fastest expansion in 3.5 years, while service price pressures fell to an 11-month low, demonstrating economic resilience that could further drive stock market gains.
- International Situation Impact: Reports of Iran making indirect contact with the US to negotiate an end to the war boosted market sentiment, although Iranian media denied the claims, the hope for an early resolution to the conflict remains.
- Oil Price Volatility: Despite crude oil prices being affected by the Iranian drone attack and the closure of the Strait of Hormuz leading to production cuts in Iraq, the market estimates a risk premium of $18 per barrel, reflecting heightened concerns over energy supply.
See More
